AU2001291133A1 - Methods of decreasing or preventing pain using spicamycin derivatives - Google Patents

Methods of decreasing or preventing pain using spicamycin derivatives

Info

Publication number
AU2001291133A1
AU2001291133A1 AU2001291133A AU9113301A AU2001291133A1 AU 2001291133 A1 AU2001291133 A1 AU 2001291133A1 AU 2001291133 A AU2001291133 A AU 2001291133A AU 9113301 A AU9113301 A AU 9113301A AU 2001291133 A1 AU2001291133 A1 AU 2001291133A1
Authority
AU
Australia
Prior art keywords
methods
decreasing
preventing pain
spicamycin derivatives
spicamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291133A
Other languages
English (en)
Inventor
David Borsook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2001291133A1 publication Critical patent/AU2001291133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AU2001291133A 2000-09-20 2001-09-20 Methods of decreasing or preventing pain using spicamycin derivatives Abandoned AU2001291133A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23438200P 2000-09-20 2000-09-20
US60/234,382 2000-09-20
PCT/US2001/029371 WO2002024146A2 (fr) 2000-09-20 2001-09-20 Procedes de reduction ou prevention de la douleur utilisant des derives de la spicamycine

Publications (1)

Publication Number Publication Date
AU2001291133A1 true AU2001291133A1 (en) 2002-04-02

Family

ID=22881151

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291133A Abandoned AU2001291133A1 (en) 2000-09-20 2001-09-20 Methods of decreasing or preventing pain using spicamycin derivatives

Country Status (9)

Country Link
US (3) US7196071B2 (fr)
EP (2) EP1328236B1 (fr)
JP (1) JP5016777B2 (fr)
AT (1) ATE504302T1 (fr)
AU (1) AU2001291133A1 (fr)
CA (1) CA2425172C (fr)
DE (1) DE60144383D1 (fr)
ES (1) ES2365473T3 (fr)
WO (1) WO2002024146A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1328236B1 (fr) * 2000-09-20 2011-04-06 The General Hospital Corporation Procedes de reduction ou prevention de la douleur utilisant des derives de la spicamycine
AU2003235403A1 (en) * 2002-05-22 2003-12-02 Fushimi Pharmaceutical Co., Ltd. Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
US7860552B2 (en) * 2004-10-01 2010-12-28 The Mclean Hospital Corporation CNS assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
JP5116071B2 (ja) 2005-07-20 2013-01-09 帝國製薬株式会社 Ｄ−アロースおよびｄ−プシコースの抗神経因性疼痛効果の利用
WO2010042212A2 (fr) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Méthodes de traitement prophylactique ou thérapeutique de la douleur à l'aide de dérivés de spicamycine
JP2015524482A (ja) 2012-08-09 2015-08-24 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を含む組成物およびその使用方法
US10262107B1 (en) * 2013-03-15 2019-04-16 Bao Tran Pharmacogenetic drug interaction management system
WO2015061481A1 (fr) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Méthodes de traitement de tumeurs liquides à l'aide de compositions comprenant des dérivés de spicamycine
US10732507B2 (en) 2015-10-26 2020-08-04 Esko-Graphics Imaging Gmbh Process and apparatus for controlled exposure of flexographic printing plates and adjusting the floor thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US6013853A (en) 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5905069A (en) 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
EP1328236B1 (fr) * 2000-09-20 2011-04-06 The General Hospital Corporation Procedes de reduction ou prevention de la douleur utilisant des derives de la spicamycine

Also Published As

Publication number Publication date
US7196071B2 (en) 2007-03-27
US20080207557A1 (en) 2008-08-28
DE60144383D1 (de) 2011-05-19
EP1328236A4 (fr) 2005-10-26
US7632825B2 (en) 2009-12-15
ES2365473T3 (es) 2011-10-06
WO2002024146A9 (fr) 2004-05-13
JP2004537494A (ja) 2004-12-16
JP5016777B2 (ja) 2012-09-05
US7375094B2 (en) 2008-05-20
US20040038927A1 (en) 2004-02-26
EP1328236B1 (fr) 2011-04-06
CA2425172C (fr) 2011-02-01
EP1328236A2 (fr) 2003-07-23
EP2305264A1 (fr) 2011-04-06
US20070161597A1 (en) 2007-07-12
WO2002024146A2 (fr) 2002-03-28
WO2002024146A3 (fr) 2003-05-22
ATE504302T1 (de) 2011-04-15
CA2425172A1 (fr) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001252135A1 (en) Therapeutic agents
WO2002012166A3 (fr) Ligands de recepteurs de melanocortines derives de triamines et procedes d'utilisation desdits ligands
HN1997000012A (es) Derivados de triazol utiles en terapia.
AU2002341374A1 (en) Miniature implantable illuminator for photodynamic therapy
AU2002341931A1 (en) Patient directed therapy management
AU2002246728A1 (en) Carboline derivatives
AU2001266890A1 (en) Tooth assembly for implements
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
AU2720199A (en) Five-membered, benzo-condensed heterocycles used as antithrombotic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
AU2002215772A1 (en) Implantable neurostimulator
AU7377200A (en) Combination therapy including camptothecin
AU6797298A (en) Halo-alkoxycarbonyl prodrugs
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2002221853A1 (en) Oxabicyclo(2.2.1)heptane derivatives as pesticidal agents
AU2001291133A1 (en) Methods of decreasing or preventing pain using spicamycin derivatives
AU2001243515A1 (en) Combination drug therapy
AU2451500A (en) Therapeutic agents
AU751887B2 (en) Guide bar including stump treatment
AU9716001A (en) Guide bar including stump treatment
AU2001270129A1 (en) Human phosphodiesterases
AU2001268653A1 (en) Combination hiv therapy including camptothecin
AU3714800A (en) Hiv therapy
AU5973600A (en) Therapeutic agents
AU5468101A (en) Novel p-aminophenols and colorants containing said compounds